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Abstract 
Single-walled carbon nanotubes (SWCNTs) have been identified as a transporter for anti-
cancer drugs, as they are capable of penetrating mammalian cell membranes and allow for a 
high drug loading due to their nanoscale dimensions and high aspect ratio. In addition, they 
can assist the targeting of therapeutic agents to the desired site of action by conjugation to 
antibodies or ligands of cancer cell surface receptors, which increases the effectiveness of the 
treatment and reduces side effects. In this work, we present a method for the triple 
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functionalisation of oxidised SWCNTs with the anti-cancer drug doxorubicin, a monoclonal 
antibody, and a fluorescent marker at non-competing binding sites. The proposed 
methodology allows for the targeted delivery of the anticancer drug to cancer cells and the 
visualisation of the cellular uptake of SWCNTs by confocal microscopy. We show that the 
complex is efficiently taken up by cancer cells with subsequent intracellular release of 
doxorubicin, which then translocates to the nucleus while the nanotubes remain in the 
cytoplasm. 
 
1. Introduction 
The development of novel anti-cancer therapies is often limited by administration problems 
of drugs, such as insolubility, inefficient distribution, lack of selectivity, and the inability of 
drugs to cross cellular barriers. Currently, most of these problems are subject of intense 
studies and in this context, many different types of drug delivery systems have been 
investigated, including quantum dots, silica nanoparticles, dendrimers, micelles, molecular 
conjugates, and liposomes [1-4]. Within the family of nanomaterials, carbon nanotubes have 
emerged as a novel tool for the delivery of therapeutic molecules into cells [5]. Carbon 
nanotubes are undoubtedly one of the most striking discoveries in the quest for new materials 
in recent years, as these unique structures possess tremendous strength [6], an extreme aspect 
ratio, and are excellent thermal and electrical conductors [7,8]. Apart from that, carbon 
nanotubes can immobilise therapeutic molecules, such as proteins, antibodies, DNA or drugs 
on their surface [9,10] or in the hollow cavity [11] and are capable of penetrating mammalian 
cell membranes [12], which makes them ideal candidates for drug delivery systems.  
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In this article, we present a new approach to functionalise single-walled carbon nanotubes 
(SWCNTs) with three different agents for multimodal drug delivery. This includes the anti-
cancer drug doxorubicin, a monoclonal antibody for molecular targeting, and the fluorescent 
marker fluorescein, all of which are attached to oxidised SWCNTs at non-competing binding 
sites. Doxorubicin was chosen as a therapeutic agent, as it is a widely used anti-cancer drug 
for the treatment of many cancers and furthermore possesses a fluorescent hydroxy-
substituted anthraquinone chromophore with an emission spectrum ranging from 500 to 750 
nm that enables intracellular tracking of the drug by confocal microscopy. The monoclonal 
antibody recognizes carcinoembryonic antigen (CEA), which is a tumour marker for the 
identification of metastatic disease following surgical resection and is relevant for a variety 
of adenocarcinomas, such as colon cancer. Fluorescein is used to label SWCNTs in order to 
colocalise them inside cells by confocal microscopy next to doxorubicin. 
The attachment of the three agents was accomplished by two different chemical approaches; 
non-covalent and covalent binding. Non-covalent chemistry has the advantage that it 
preserves the structure of SWCNTs and thus their unique properties. However, a non-
covalent bond is susceptible to environmental factors, such as pH and salt concentration, and 
is in general less stable than a covalent bond. In contrast to this, covalent attachment of 
molecules to carbon nanotubes depends on the introduction of chemically reactive groups to 
their relatively inert sp2 structure, which can only be achieved by harsh treatments, such as 
oxidation with concentrated inorganic acids [13], fluorination by elemental fluorine [14] or  a 
1,3 dipolar cycloaddition reaction [15] and inevitably introduces defects to the nanotube 
structure. 
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On the basis of these considerations, non-covalent functionalisation was chosen for 
attachment of doxorubicin to allow for its release after cellular uptake, whereas covalent 
functionalisation was employed to attach fluorescein and CEA antibodies to oxidised 
SWCNTs. The latter was achieved by using the hydrophilic protein bovine serum albumin 
(BSA) as a multifunctional linker. In total, BSA possesses 60 amino groups in lysine chains 
and 99 carboxylic groups as part of glutamic and aspartic acid residues. Those residues 
located on the protein surface are available for conjugation reactions and thus provide two 
different types of binding sites for the covalent attachment of molecules. In our approach, 
BSA is conjugated to carboxylic groups of oxidised SWCNTs by one of its amine groups, to 
NHS-fluorescein via the remaining amine groups, and to monoclonal CEA antibodies via its 
carboxylic groups. Since multiple copies of fluorescein and antibodies can be attached to one 
BSA molecule, the degree of coupling is increased manifold. Figure 1 shows a schematic 
illustration of the structure, which we propose for the nanotube-drug-BSA conjugates. The 
distribution of functional groups after acid oxidation of carbon nanotubes has already been 
investigated in previous studies, which showed that functional groups are found at the ends 
of the tubes and along the sidewalls [16,17]. Results obtained by atomic force microscopy 
(AFM) demonstrate a similar distribution for BSA molecules attached to functional groups of 
oxidised, doxorubicin-loaded SWCNTs in our experiments (insert of Figure 1). 
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Figure 1 Schematic illustration of the doxorubicin-fluorescein-BSA-antibody-SWCNT 
complexes (red=doxorubicin, green=fluorescein, light blue=BSA, dark blue=antibodies). 
Insert: AFM image of doxorubicin-fluorescein-BSA-SWCNT complexes (without 
antibodies). 
 
The cellular uptake of drug-antibody-SWCNT complexes was studied by means of confocal 
microscopy using CEA-expressing WiDr colon cancer cells. The design of the nanotube-drug 
complexes is based on the hypothesis that functionalised SWCNTs are taken up by WiDr 
cells by endocytosis. Following uptake, the lower pH inside endosomes is expected to trigger 
the release of doxorubicin from the nanotube due to increased hydrophilicity of the drug, 
which can then translocate to the nucleus and exert its cytotoxic action.  
 
2. Experimental Details 
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2.1. Material 
SWCNTs were purchased from NanoLab, Inc. (produced by CVD using iron (ferrocene) as 
catalyst, purity > 60%, length 1-5 µm, Lot No. 90907). WiDr human colon cancer cells were 
obtained from LGC Promochem (Teddington, UK; Catalog No. CCL-218). The monoclonal 
CEA antibody with specificity for CD66e was purchased from AbD Serotec (MCA1744F). 
MEM (31095-029) and Opti-MEM medium (31985-047) were obtained from Invitrogen 
(Paisley, UK). Doxorubicin hydrochloride (44583), 5(6)-carboxyfluorescein N-
hydroxysuccinimide ester (NHS-fluorescein, 21878), bovine serum albumin (BSA, A3294), 
1-ethyl-3-[3-dimethyl-aminopropyl] carbodiimide hydrochloride (EDC, E1769), N-
hydroxysulfo-succinimide (sulfo-NHS, 56485), 2-mercaptoethanol (63700), and 
ethanolamine hydrochloride (E6133) were purchased from Sigma-Aldrich (Poole, UK). 
 
2.2. Oxidation and Purification of SWCNTs 
As-prepared SWCNTs are usually contaminated with metal catalyst particles, amorphous 
carbon and graphitic nanoparticles. However, the application of carbon nanotubes for 
biomedical purposes has created a demand for high purity material, especially if the sidewalls 
of carbon nanotubes are to serve as platform for the non-covalent attachment of 
biomolecules. Li et al. have compared different oxidation methods for CVD-synthesized 
SWCNTs and found that nitric acid pre-sonication, followed by refluxing in a mixture of 
concentrated acids yield the best results with respect to purity [18]. This two-step process 
was slightly adapted for the work presented here. In the first step, 100 mg of SWCNTs were 
incubated in 20 mL of concentrated nitric acid and sonicated with a tip sonicator for 6x 10s 
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to disentangle the tubes and break up bundles. Subsequently, the mixture was incubated in a 
95 °C water bath for 2h. To remove dissolved metal catalyst particles, the oxidation treatment 
was followed by a centrifugation step at 3000 g for 30 min. After discarding the supernatant, 
the purified tubes were washed twice with bi-distilled water. In the second step, the purified 
sample of SWCNTs (~100 mg) was dispersed in a 3:1 mixture of concentrated nitric and 
sulfuric acid and sonicated for 6x 10s with a tip sonicator. Subsequently, the mixture was 
refluxed at 110 °C for 2h, followed by three washing steps with water and centrifugation at 
3000 g for 30 min to remove excess acid in the supernatant. Finally, the oxidised SWCNTs 
were vacuum filtered using a 0.2 µm polycarbonate filter (Whatman) until the eluate was 
clear and of neutral pH. The filter cake was dried overnight at room temperature, weighed, 
and resuspended in water to a concentration of 5 mg/mL. This material will henceforth be 
referred to as “oxSWCNTs”. 
  
2.3. Characterisation of pristine and oxidised SWCNTs 
The term “carbon nanotube” does not describe a simple, chemical structure, but a whole class 
of materials, which vary in their numbers of walls, diameter distribution, length distribution, 
chirality, purity, catalyst material, impurity species and defects. Thus, characterisation of the 
applied material is crucial in order to ensure quality and reproducibility. The nanotubes in 
this work were characterised by scanning electron microscopy (SEM), high resolution 
transmission electron microscopy (HR-TEM), atomic force microscopy (AFM), Raman 
spectroscopy, and thermogravimetric analyis (TGA). 
 
2.3.1. SEM 
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All SEM images in this study were obtained using a FEI 200 Nova NanoSEM system. 
Powder samples were prepared by placing a small amount of SWCNT powder onto a piece 
of double-sided adhesive tape stuck to a metal stub. Liquid samples were prepared by placing 
a 2 µL drop of a 10 µg/mL SWCNT suspension onto a small piece of silicon stuck to a metal 
stub and evaporating residual water using a hot plate. The metal stubs holding the samples 
were then placed into the vacuum chamber of the microscope and images acquired using a 
voltage of 10 kV and a spot size of 3.0 to 5.0. 
 
2.3.2. HR-TEM 
The HR-TEM work presented in this report was carried out using a High Resolution 
Transmission Electron Microscope JEOL-EM 2100. For sample preparation, oxSWCNTs 
were diluted with ethanol and briefly sonicated in a water bath for dispersion. 3-5 drops of 
this suspension were then placed onto a 300 mesh copper TEM grid and excess liquid was 
removed by touching one edge of the grid with filter paper. 
 
2.3.3. AFM 
For AFM sample preparation, oxSWCNTs were diluted with water to obtain a concentration 
of 10 µg/mL. A droplet of 2 µL was placed onto a freshly cleaved mica substrate (1 cm2) and 
was dried with help of compressed air. AFM measurements were performed using a Veeco 
Dimension 3100 Atomic Force Microscope in tapping mode. To obtain a length distribution, 
several AFM images were taken at a frame size of 5 µm x 5 µm and the lengths of 500 
nanotubes was measured using “Gwyddion 2.9”, a free SPM data visualization and imaging 
tool released under the GNU General Public License. 
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2.3.4. Raman Spectroscopy 
Samples for Raman spectroscopy were prepared by placing a small quantity of carbon 
nanotube powder or a droplet of an oxSWCNT suspension between a glass slide and a cover 
slip. Measurements were performed using a NT-MDT NTEGRA Spectra Probe 
NanoLaboratory with excitation at 633 nm.  
 
2.3.5. TGA 
For a typical TGA experiment, ~ 1 mg of nanotube material was placed in the sample holder 
in the furnace of a Rheometric Scientific TG 760 series and the material was heated up at a 
rate of 10 °C/min, while the weight was measured and recorded continuously. 
 
2.4. Triple functionalisation of SWCNTs with doxorubicin, fluorescein, and CEA 
antibodies 
 
Labeling of BSA with fluorescein 
3 mg NHS-fluorescein (10 mg/mL in DMSO) was mixed with 150 mg BSA in sodium 
phosphate buffer 20 mM pH 8.5, followed by incubation for 2h in darkness at room 
temperature while stirring. To remove excess fluorescein, the mixture was filtered and 
washed repeatedly using Amicon Ultra® 30 kDa centrifugal filtration devices (Millipore) 
until the eluate was clear. The fluorescein-BSA conjugates were resuspended in sodium 
phosphate buffer 20 mM (pH 7.4) at a BSA concentration of 5 mg/mL. 
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The degree of labeling (fluorescein/BSA molar ratio) was determined by separately 
calculating the protein and fluorophore molar concentrations of the conjugate based on 
absorbance measurements and expressing these concentrations as a ratio. Absorbance at 280 
nm (A280) was used to determine the protein concentration in the sample. However, because 
fluorescent dyes also absorb at 280 nm, a correction factor must be used to adjust for the 
amount of A280 contributed by the dye. The correction factor (CF) equals the A280 of the dye 
divided by the Amax of the dye and was determined to be 0.26 for NHS-fluorescein (data not 
shown).  
In the first step, the molar concentration of BSA ( BSAc ) was calculated according to equation 
(1) which is derived from Beer-Lambert’s Law ( lcA   ) with A being the absorbance of 
the respective molecules, CF being the correction factor, ε being the molar extinction 
coefficient, l being the path length of the cuvette and DF being the dilution factor:  
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In the second step, the degree of labeling (moles fluorescein per mole protein) was calculated 
according to equation (2):  
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Non-covalent attachment of doxorubicin to oxidised SWCNTs 
150 µL of a 5 mg/mL oxSWCNT suspension was dispersed in 15 mL sodium phosphate 
buffer 20 mM pH 8.5 and 3 mL of a 5 mM doxorubicin hydrochloride solution was added. 
The mixture was sonicated in a water bath for 15 min and incubated overnight while stirring. 
Unbound doxorubicin was removed by filtering and washing using Amicon Ultra® 30 kDa 
centrifugal filter devices (Millipore). Finally, the doxorubicin-loaded SWCNTs were 
resuspended in 15 mL sodium phosphate buffer 20 mM pH 7.4 at a SWCNT concentration of 
50 µg/mL and 5 mL of these complexes were kept as a control sample, whereas the other 10 
mL were used for further conjugation steps. In order to determine how much doxorubicin 
was bound to the nanotubes, the eluate of the centrifugation steps containing unbound 
doxorubicin were collected and analysed by UV/vis absorption spectroscopy by measuring 
the absorbance at the first excitation maximum of doxorubicin at 490 nm.  
 
Connection of fluorescein-labeled BSA and doxorubicin-loaded SWCNTs 
10 mL doxorubicin-loaded SWCNTs were dispersed in 10 mL sodium phosphate buffer 20 
mM pH 8.5. If necessary, the pH was adjusted to 8.5 by means of a trisodium phosphate 20 
mM solution. Next, 1 mL of a 20 mM EDC solution and 1 mL of a 50 mM sulfo-NHS 
solution were added and the mixture was incubated for 5 min at room temperature. To 
quench excess EDC, 70 µL 2-mercaptoethanol was added to a final concentration of 20 mM. 
To start the coupling reaction, 10 mL of the fluorescein-labeled BSA solution (5 mg/mL 
BSA) was added and the reaction allowed to proceed for 2h at room temperature. Finally, 1 
mL of a 250 mM ethanolamine hydrochloride solution was added to quench the reaction. The 
nanotube complexes were washed by vacuum filtration using 0.2 µM polycarbonate filters 
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(Whatman) and were resuspended in 10 mL sodium phosphate buffer 20 mM pH 7.4. 5 mL 
of these complexes were kept for experiments and the remaining 5 mL were used for the last 
conjugation step. 
 
Attachment of monoclonal CEA antibodies to doxorubicin-fluorescein-BSA-SWCNT 
conjugate 
5 mL of the doxorubicin-fluorescein-BSA-SWCNT complexes in water were mixed with 5 
mL sodium phosphate buffer 50 mM pH 8.5. If necessary, the pH was adjusted to 8.5 by 
means of a trisodium phosphate 20 mM solution. Next, 500 µL of a 20 mM EDC solution 
and 500 µL of a 50 mM sulfo-NHS solution were added and the mixture was incubated for 5 
min at room temperature. To quench excess EDC, 35 µL 2-mercaptoethanol was added to a 
final concentration of 20 mM. Subsequently, 5 mL of a 1 µg/mL anti-CEA antibody solution 
was added and the reaction allowed to proceed for 2h at room temperature in darkness while 
stirring. Finally, 500 µL of a 250 mM ethanolamine hydrochloride solution was added to 
quench the reaction and the nanotube complexes were washed by vacuum filtration using 0.2 
µM polycarbonate filters (Whatman) and resuspended in 5 mL sodium phosphate buffer 20 
mM pH 7.4. 
 
2.5. Delivery of the drug-SWCNT conjugates to WiDr colon cancer cells 
The WiDr human colon cancer cell line was derived from a 78-year old female Caucasian 
and expresses carcinoembryonic antigen (CEA) at a rate of 118 ng/106 cells/10 days 
according to LGC Promochem’s product information sheet. Growth medium is Eagle’s 
Minimal Essential Medium (MEM) containing 2 mM L-glutamine, which was modified to 
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contain 1.0 mM sodium pyruvate, 0.1 mM non-essential amino acids, 10% fetal bovine 
serum, and penicillin/streptomycin (100 units/mL penicillin and 100 µg/mL streptomycin in 
the final formulation). The medium is formulated for use with a 5% CO2 in air atmosphere. 
For the cell studies, WiDr cells were grown on cover slips in a 6-well plate until 70-80% 
confluent. The prepared doxorubicin-fluorescein-BSA-SWCNT conjugates and the controls 
were mixed with Opti-MEM medium at a 1:1 ratio (500 µL complexes + 500 µL medium), 
resulting in final SWCNT concentrations of 25 µg/mL. The mixtures were sonicated for 3x 
10s using a tip sonicator and remaining agglomerates removed by centrifugation for 60 s at 
3000 g. Next, WiDr cells were incubated with 1 mL of the sample or control solutions in 
Opti-MEM medium for 4h at 37 °C. The cells were then washed three times with PBS and 
fixed by incubation with freshly prepared 4% paraformaldehyde solution at room 
temperature for 30 min. Finally, the cells were washed twice with PBS and mounted on a 
glass slide. 
Confocal microscopy was carried out using a Zeiss LSM 510 confocal microscope equipped 
with an Argon/2 laser in multi-channel mode. The excitation wavelength was set to 488 nm 
for fluorescein and doxorubicin. Emission of fluorescein was detected between 500 and 530 
nm and emission of doxorubicin was detected from 650 to 710 nm. Images were taken at 63x 
magnification by means of a C-Apochromat 63x/1.4 Oil objective. 
 
3. Results and Discussion 
 
3.1. Characterisation of oxidised SWCNTs 
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Pristine and oxidised Nanolab SWCNTs were characterised by SEM, HR-TEM, AFM, 
Raman spectroscopy, and TGA in order to evaluate their purity and their physical and 
chemical properties.  
 
Figure 2 Characterisation of oxidised SWCNTs: a) SEM image, magnification = 120K; 
b) HR-TEM image at two magnifications; c) AFM image (frame size 5 µm2); d) Raman 
spectrum (excitation = 633 nm) 
 
  15 
The SEM image of oxidised SWCNTs (Fig. 2a) demonstrates that acid oxidation entangles 
clumps of nanotubes that are present in the bulk sample. The oxidised SWCNTs seem to 
form small bundles which are covered with a thin layer of a material that has been shown to 
consist of decomposed products of carbonaceous impurities [19], such as partially oxidised 
graphitic fragments, and amorphous carbon. Thermal oxidation can be applied to remove 
these remaining impurities; however, they improve the solubilisation properties of carbon 
nanotubes by acting as a surfactant [20]. The TEM picture in Fig. 2b reveals more detailed 
information about the bundling state of the nanotubes. Apart from single nanotubes, bundles 
of up to ~15 nanotubes can be observed, which are again covered with the same oxidation 
debris. AFM analysis of carbon nanotubes was applied to extract a height profile and to 
generate a length distribution of the oxidised SWCNTs (Fig. 2c, Fig. 3). The height profile 
features seven SWCNT bundles with diameters in the range of 2.0 to 4.0 nm. Given that the 
average diameter of a single SWCNT is about 1 nm, this corresponds to bundles consisting of 
3 to 10 nanotubes. The length distribution was used to quantify the extent of shortening by 
the oxidation process. The maximum of the size distribution after oxidation lies at 450 nm 
and 83% of the tubes were found to be between 200 nm and 1000 nm long. Considering that 
the lengths of SWCNTs in the pristine sample ranged from 1 to 5 µm, this corresponds to a 
shortening of 80%. The Raman spectrum (Fig. 2d) shows all features that are characteristic 
for SWCNTs: the radial breathing mode (RBM), the D-band and the G-band [21,22]. The 
RBM results from low-energy radial vibrations of carbon atoms in the nanotube backbone 
and hence its frequency is inversely proportional to the tube diameter  according to 
12.5 /5.223  d , where d is the tube diameter in nm and  is Raman shift in wave 
numbers [23]. The RBM in the Raman spectrum of Fig. 2d ranges from 170 cm-1 to 410 cm-1; 
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corresponding to a diameter distribution between 0.56 and 1.42 nm with an average diameter 
of approximately 1 nm. Maximum intensities are observed at 228 cm-1, 284 cm-1, and 403 
cm-1; relating to accumulated diameters at 1.06 nm, 0.82 nm, and 0.57 nm. The disorder-
induced D-band at 1380 cm-1 indicates the presence of defective, sp3 hybridised sites on 
SWCNTs and the G-band at 1640 cm-1 is a tangential vibrational mode characteristic to all 
graphitic materials. The G/D intensity ratio is a good indicator for the quality of bulk 
samples. Here, the G/D ratio was found to be 13.95, demonstrating a low quantity of defects. 
 
 
Figure 3 Height profile (a) of oxSWCNTs extracted from Fig. 2c and length distribution 
(b) of oxSWCNTs (n=500) 
 
Last, but not least, oxidised SWCNTs were analysed by TGA to determine the amount of 
metal catalyst in the bulk sample. The metal residue was found to be 11.2% for pristine 
SWCNTs and 11.6% for oxidised SWCNTs (data not shown). This indicates that the present 
metallic catalyst particles are encapsulated in carbon shells (so-called nanoonions) [24], 
which protect them from acid oxidation, but also prevent them from being released in 
biological environments and causing toxic effects.  
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3.2. Triple functionalisation of SWCNTs with doxorubicin, fluorescein, and CEA 
antibodies 
We developed a method for the triple functionalisation of SWCNTs, which allows for the 
attachment of a monoclonal antibody for targeting purposes, an anti-cancer drug, and a 
fluorescent dye at non-competing binding sites to enable visualisation of cellular uptake. The 
functionalisation procedure is a critical process comprising 4 steps and can easily result in 
many kinds of unwanted crosslinking reactions. Hence, the reaction parameters have to be 
selected and adjusted carefully. In the first step, the protein BSA is labeled with the amine-
reactive dye NHS-fluorescein. Here, it is crucial to find the optimal NHS-fluorescein 
concentration in order to leave enough free amino groups on the BSA for the later attachment 
of carbon nanotubes. However, leaving too many free binding sites would lead to 
crosslinking of nanotubes via BSA and thus to precipitation. Optimisation of the 
fluorescein/BSA ratio was performed by testing three different weight ratios (1:20, 1:50, and 
1:100) in their binding properties to SWCNTs (see next paragraph). Furthermore, the degree 
of fluorescein labeling was determined by UV/vis absorption spectroscopy (see equations 1 
and 2). A 1:20 weight ratio of fluorescein/BSA resulted in a degree of labeling of 3.99, 
whereas a 1:50 weight ratio correlated with a degree of 2.19 and a 1:100 weight ratio with a 
degree of 1.19.  
 
In the second step of the coupling reaction, the anti-cancer drug doxorubicin is non-
covalently attached to the sidewalls of oxidised carbon nanotubes via -stacking and 
hydrophilic interactions with carboxylic groups. The strength of this non-covalent binding is 
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pH dependent: At a low pH, the amino group in the sugar moiety of doxorubicin is 
protonated, which increases the molecule’s hydrophilicity and thus its solubility in water. 
However, at a higher pH, the amino group becomes deprotonated, resulting in stronger 
hydrophobic interactions with the nanotubes’ side walls and lower solubility in water. Liu et 
al. have attached doxorubicin non-covalently to the side walls of SWCNTs by overnight 
incubation at pH 9 [25].  However, Janssen et al. reported that doxorubicin hydrochloride has 
its maximum stability at pH 4 [26] and processing the drug at pH 9 may cause its degradation 
and thus the loss of its therapeutic efficiency. Thus, to ensure a high drug loading whilst 
maintaining doxorubicin’s therapeutic properties, the reaction was carried out at a slightly 
lower pH of 8.5. According to Beijnen et al., who generated a pH-dependent decomposition 
profile for doxorubicin at 50 °C corrected for buffer and ionic strength influences [27], the 
decomposition rate of doxorubicin at pH 8.5 is approximately 35% less than at pH 9.0. 
The amount of doxorubicin bound to the nanotubes was calculated by determining the 
quantity of unbound doxorubicin in the eluate of the filtration step by UV/vis absorption 
spectroscopy. It was found that 87.5% of doxorubicin had attached to the nanotubes, whereas 
12.5% had been washed off. In terms of weight, the ratio of doxorubicin to oxidised 
SWCNTs is 20:1, which demonstrates the enormous binding capacity of the nanotubes. Liu 
et al. have determined a weight ratio of 4:1 in a similar experiment [25] – however, the 
surface of their (non-oxidised) SWCNTs was already covered with phospholipid-PEG-
molecules to a certain extent, which were previously applied to solubilise the nanotubes. 
 
In the third step, the fluorescein-labeled BSA and doxorubicin-loaded SWCNTs are 
conjugated. In order to avoid non-specific binding of BSA to the nanotubes’ sidewalls, it is 
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crucial to load them with doxorubicin before conjugation with fluorescein-BSA. In order to 
find out the optimal fluorescein/BSA ratio, three fluorescein/BSA complexes at different 
weight ratios (1:20, 1:50, and 1:100) were tested with respect to their binding to SWCNTs in 
a qualitative and quantitative way. The corresponding molar ratios are 7.0, 2.8, and 1.4. We 
expected a high fluorescein/BSA ratio to result in low binding due to most of the BSA’s 
binding sites being occupied by fluorescein molecules. Accordingly, the optimal ratio would 
correlate to exactly one free binding site per BSA molecule, whereas several free binding 
sites would lead to crosslinking of nanotubes, resulting in agglomeration and a lower 
percentage of binding. These assumptions could be confirmed experimentally with optimal 
results having been achieved for a 1:50 ratio, which was thus used for all further 
experiments.  
 
Table 1 Influence of the fluorescein/BSA ratio on the binding of the respective 
conjugates to SWCNTs 
Fluorescein/BSA ratio (weight) 1:20 1:50 1:100 
Degree of labeling 3.85 2.30 1.26 
% of fluorescein-BSA bound to 
SWCNTs at the described 
experimental conditions 
19.33% 54.81% 14.56% 
Agglomeration little little much 
 
In the last step, monoclonal antibodies are attached to the still unoccupied carboxylic groups 
of the BSA (now part of the doxorubicin-fluorescein-BSA-SWCNT complexes). Here, it has 
to be considered that whenever two protein ligands undergo a coupling reaction catalysed by 
EDC and sulfo-NHS, excessive EDC has to be quenched by 2-mercaptoethanol, as otherwise 
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carboxylic groups of both coupling partners (BSA and CEA antibodies) would be activated 
and cause extensive crosslinking.  
 
3.3. Delivery of the drug-SWCNT conjugates to WiDr colon cancer cells 
To study the uptake of doxorubicin-fluorescein-BSA-SWCNT complexes by WiDr colon 
cancer cells and investigate the suitability of functionalised SWCNTs as a drug delivery 
system, WiDr cells were incubated with the nanotube-drug complexes for 4h. Afterwards, 
laser scanning confocal microscopy was applied to track the location of doxorubicin and the 
fluorescein-labeled SWCNTs inside cells. Confocal microscopy is a special type of 
fluorescence microscopy, which only detects light within the focal plane by eliminating out-
of-focus information via point illumination and a pinhole in front of the detector. 
 
 
Figure 4 Confocal image of WiDr cells incubated with doxorubicin-fluorescein-BSA-
SWCNT complexes (a=emission measured at 500-530 nm (fluorescein), b=emission 
measured at 650-710 nm (doxorubicin), c=transmitted light image showing all channels) 
 
As mentioned earlier, the whole drug delivery experiment is based on the hypothesis that 
functionalised SWCNTs are taken up by WiDr cells by endocytosis. We expected the lower 
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pH inside endosomes to trigger the release of doxorubicin from the nanotubes due to 
increased hydrophilicity. Indeed, Fig. 4 clearly demonstrates, that doxorubicin (red) does not 
colocalise any longer with the fluorescein-labeled SWCNTs (green) after internalization by 
WiDr cells, but was found to accumulate in the nuclei of cells (seen as round structures 
positioned in the in the centre of the cell). The fluorescently-labeled nanotubes, however, are 
mainly observed outside the nuclei within the cytoplasm. Areas in the cell where doxorubicin 
and fluorescein-labeled nanotubes colocalise can be observed along the border between the 
cytoplasm and the nucleus, the so-called “nuclear envelope”, and on the cell membrane. The 
delivery efficiency in this experiment was 100%, meaning that all cells have taken up the 
SWCNT complexes. 
 
 
Figure 5 Confocal images of controls:  a) fluorescein-BSA; b) doxorubicin-SWCNTs; c) 
doxorubicin 10 M 
 
Several controls were performed to corroborate these findings, including fluorescein-BSA 
conjugates, doxorubicin-SWCNT complexes without fluorescein-BSA, and doxorubicin 
alone. Fig. 5a shows a low level of fluorescence, thus indicating that fluorescein-BSA 
conjugates are only able to enter cells to a very small extent, which demonstrates that 
  22 
SWCNTs play an important role as a delivery system. However, when comparing Fig. 5b and 
5c it becomes obvious that this is not the case for doxorubicin: due to its molecular structure, 
the drug is able to cross cell membranes without the help of a carrier system and accumulates 
in the cell nuclei, as shown before. Nevertheless, the nanotubes still play an important role, 
as they enable molecular targeting via the attachment of monoclonal antibodies and are 
crucial for the delivery of drugs that are not taken up by cells under normal conditions.  
 
Apart from this, more work needs to be done with regard to the question whether carbon 
nanotubes are able to enter nuclei of cells. This study clearly showed that the nanotubes 
remained in the cytoplasm under the applied conditions. The same behavior was 
demonstrated by Kam et al., who studied the uptake of Cy3-DNA-wrapped SWCNTs by 
Hela cells and detected fluorescence in the cytoplasm only [28]. However, Pantarotto et al. 
have conducted a study where two different carbon nanotube conjugates were introduced into 
human and murine fibroblasts and found that water-soluble SWCNTs conjugated to 
fluorescein isothiocyanate (FITC) accumulated in the cytoplasm, whereas SWCNTs 
conjugated to a FITC-labeled peptide were observed to distribute inside the nucleus [12]. 
Furthermore, Cheng et al. recently showed that FITC-PEG-SWCNTs accumulated in the 
nuclei of several mammalian cell lines [29]. This indicates that the ability of CNTs to cross 
cellular barriers, such as the nuclear envelope, is dependent on the type of functionalisation.  
 
4. Conclusion 
This work presents a novel functionalisation approach to equip oxidised SWCNTs with three 
different agents for multimodal drug delivery. It is demonstrated that SWCNTs can 
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successfully transport a potent anti-cancer drug to human cancer cells with subsequent 
translocation of the drug to the nucleus, while the SWCNTs remain in the cytoplasm. This 
finding suggests that SWCNTs may be used to enhance cellular pharmacokinetics and have 
considerable implications for improving anti-cancer drug delivery. However, targeting and 
toxicity of SWCNTs remain important issues that need to be examined in greater depth and 
will be addressed in future studies. The triple functionalisation methodology presented in this 
article already incorporates the attachment of monoclonal antibodies for molecular targeting 
and current work is in progress in order to investigate, whether the uptake of CEA antibody-
tagged SWCNT conjugates by WiDr colon cancer cells is increased in comparison to 
untagged conjugates.   
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